Top

Published in:

01-09-2018 | Clinical Study

Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI

Authors: Andrea Romano, Luca Pasquini, Alberto Di Napoli, Francesca Tavanti, Alessandro Boellis, Maria Camilla Rossi Espagnet, Giuseppe Minniti, Alessandro Bozzao

Published in: Journal of Neuro-Oncology | Issue 2/2018

Abstract

Purpose

The identification of prognostic biomarkers plays a pivotal role in the management of glioblastoma. The aim of this study was to assess the role of magnetic resonance dynamic susceptibility contrast imaging (DSC-MRI) with histogram analysis in the prognostic evaluation of patients suffering from glioblastoma.

Materials and methods

Sixty-eight patients with newly diagnosed pathologically verified GBM were retrospectively evaluated. All patients underwent MRI investigations, including DSC-MRI, surgical procedure and received postoperative focal radiotherapy plus daily temozolomide (TMZ), followed by adjuvant TMZ therapy. Relative cerebral blood volume (rCBV) histograms were generated from a volume of interest covering the solid portions of the tumor and statistically evaluated for kurtosis, skewness, mean, median and maximum value of rCBV. To verify if histogram parameters could predict survival at 1 and 2 years, receiver operating characteristic (ROC) curves were obtained. Kaplan–Meier method was used to calculate patient’s overall survival.

Results

rCBV kurtosis and rCBV skewness showed significant differences between subjects surviving > 1 and > 2 years, According to ROC analysis, the rCBV kurtosis showed the best statistic performance compared to the other parameters; respectively, values of 1 and 2.45 represented an optimised cut-off point to distinguish subjects surviving over 1 or 2 years. Kaplan–Meier curves showed a significant difference between subjects with rCBV kurtosis values higher or lower than 1 (respectively 1021 and 576 days; Log-rank test: p = 0.007), and between subjects with rCBV kurtosis values higher or lower than 2.45 (respectively 802 and 408 days; Log-rank test: p = 0.001).

Conclusion

The histogram analysis of perfusion MRI proved to be a valid method to predict survival in patients affected by glioblastoma.

Hegi E, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6 methylguanine—DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 6:1871–1874CrossRef

Rivera AL, Pelloski CE, Gilbert MR et al (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neurooncology 2:116–121

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 10:997–1003CrossRef

Paz MF, Yaya-Tur R, Rojas-Marcos I et al (2004) CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10:4933–4938CrossRefPubMed

Cao Y, Tsien CI, Nagesh V et al (2006) Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 64:876–885 (Erratum in: Int J Radiat Oncol Biol Phys 2006;65:960).CrossRefPubMed

Puig J, Blasco G, Daunis-I-Estadella J, Alberich-Bayarri A et al (2016) High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study. Neuroradiology 58:17–26CrossRefPubMed

Jabehdar Maralani P, Melhem ER, Wang S et al (2015) Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas. Eur Radiol 25:2738–2744CrossRefPubMed

Thomsen H, Steffensen E, Larsson EM (2012) Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas. Acta Radiol 53:95–101CrossRefPubMed

Kim HS, Kim JH, Kim SH, Cho KG, Kim SY (2010) Posttreatment high-grade glioma: usefulness of peak height position with semiquantitative MR perfusion histogram analysis in an entire contrast-enhanced lesion for predicting volume fraction of recurrence. Radiology 256:906–915CrossRefPubMed

10.

Hamilton MG, Roldán G, Magliocco A, McIntyre JB, Parney I, Easaw JC (2011) Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol 102:255–260CrossRefPubMed

11.

Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R (2015) Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (review). Int J Oncol 47:417–428CrossRefPubMedPubMedCentral

12.

Parkinson JF, Wheeler HR, Clarkson A et al (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71–78CrossRefPubMed

13.

Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ (2012) Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology 264:834–843CrossRefPubMed

14.

Quant EC, Wen PY (2011) Response assessment in neuro-oncology. Curr Oncol Rep 13:50–56CrossRefPubMed

15.

Rosen BR, Belliveau JW, Vevea JM, Brady TJ (1990) Perfusion imaging with NMR contrast agents. Magn Reson Med 14:249–265CrossRefPubMed

16.

Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR (1996) High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 36:715–725CrossRefPubMed

17.

Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867PubMed

18.

Law M, Oh S, Johnson G et al (2006) Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58:1099–1107CrossRefPubMed

19.

Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol 25:214–221PubMed

20.

Hirai T, Murakami R, Nakamura H et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505–1510CrossRefPubMed

21.

Paik W, Kim HS, Choi CG, Kim SJ (2016) Pre-operative perfusion skewness and kurtosis are potential predictors of progression-free survival after partial resection of newly diagnosed glioblastoma. Korean J Radiol 17:117–126CrossRefPubMedPubMedCentral

22.

Lee J, Jain R, Khalil K et al (2016) Texture feature ratios from relative CBV maps of perfusion MRI are associated with patient survival in glioblastoma. AJNR Am J Neuroradiol 37:37–43CrossRefPubMed

23.

Ebrahimi A, Skardelly M, Bonzheim I et al (2016) ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 4:60CrossRefPubMedPubMedCentral

24.

Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT//Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016CrossRefPubMedPubMedCentral

25.

Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199CrossRefPubMed

26.

Ryoo I, Choi SH, Sohn CH et al (2013) Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles. PLoS ONE 8:e71704CrossRefPubMedPubMedCentral

27.

Hempel JM, Schittenhelm J, Klose U et al (2018) In vivo molecular profiling of human glioma: cross-sectional observational study using dynamic susceptibility contrast magnetic resonance perfusion imaging. Clin Neuroradiol. https://doi.org/10.1007/s00062-018-0676-2 PubMedCrossRef

Title: Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI
Authors: Andrea Romano
Luca Pasquini
Alberto Di Napoli
Francesca Tavanti
Alessandro Boellis
Maria Camilla Rossi Espagnet
Giuseppe Minniti
Alessandro Bozzao
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2887-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI

Abstract

Purpose

Materials and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

GOLPH3 promotes glioma progression via facilitating JAK2–STAT3 pathway activation

Leptomeningeal disease in uveal melanoma: a case series

Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature

MR-spectroscopic imaging of glial tumors in the spotlight of the 2016 WHO classification

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma

Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors